Back

Founder effect of a pathogenic TNNT2 variant in the northwest of Spain responsible for a non-severe phenotype of hypertrophic cardiomyopathy.

28 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy: genotypes and phenotypes Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Maria Valverde

Health in Code, Coruna, A (Spain)

6 More presentations in this session

Presentation thumbnail
The Australian Genetic Heart Disease Registry: Insights into healthcare utilisation and outcomes for genetic heart disease
Ms A. Butters (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Family screening in hypertrophic cardiomyopathy - clinical and genetic yield at baseline
Doctor E. Silajdzija (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Clinical significance and genetic basis of hypertrophic cardiomyopathy with apical phenotype: comparison of pure-apical form and distal-dominant form
Doctor K. Sugiura (Nankoku, JP)
Abstract Slides Video
Presentation thumbnail
Epigenetic study of the differential phenotypic expression of a hypertrophic cardiomyopathy-related pathological variant at MYBPC3 in a cohort of monozygotic twins
Mr A. Penarroya (Oviedo, ES)
Abstract Slides Video
Presentation thumbnail
A novel strategy for key gene identification in hypertrophic cardiomyopathy based on cuproptosis and multiple WGCNA analyses
Doctor Y. Xiao (Changsha, CN)
Abstract Slides

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: genotypes and phenotypes

The Event

Event poster

ESC Congress 2023

28 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Natural history of TNNT2 gene mutation carriers with familial hypertrophic cardiomyopathy: a long follow up study
thumbnail
Congress Presentation
Founder novel mutations in hypertrophic cardiomyopathy patients in Italy
thumbnail
Congress Presentation
Genotype-phenotype relationship in hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources